ProPhase Labs is navigating through financial challenges by implementing cost reductions and restructuring efforts. The company is focused on upcoming liquidity events, including the potential sale of Nebula Genomics and significant collections from Crown Medical, which are expected to improve its financial position. However, the shortfall in COVID testing revenue and challenges in maintaining NASDAQ compliance present ongoing risks.

Company Guidance -

Q3 2025

In the call discussing ProPhase Labs' first quarter 2025 results, CEO Ted Karkus provided guidance highlighting several key metrics and expectations for the company. He emphasized the anticipated commercialization of the BE-Smart Esophageal Cancer Test later in the year, targeting approximately 7 million endoscopies annually in the U.S., with a potential reimbursement of $1,000 to $2,000 per test. Karkus also discussed the sale of Nebula Genomics, stating that the company's genomic data set is equivalent to over 150 million ancestry tests, and potential acquisition interest could align with the company's market cap. Additionally, he mentioned plans to address liquidity through debt financing, with expected substantial cash flow from Crown Medical collections and the sale of Nebula Genomics in the latter half of 2025. The company also addressed NASDAQ compliance, expecting a six-month extension to meet listing requirements, and outlined cost-cutting measures, including reducing headcount from 96 to 25 employees since December.

Pharmaloz Manufacturing Sale

ProPhase Labs sold the Pharmaloz manufacturing facility for $23 million, which significantly increased their shareholders' equity and cleaned up the balance sheet.

Cost Reduction and Restructuring

ProPhase Labs has reduced its headcount from 96 employees to 25 and shut down the genomics laboratory, resulting in significant overhead cost reductions.

Potential Sale of Nebula Genomics

ProPhase Labs is exploring strategic alternatives for Nebula Genomics, including a potential sale, which could significantly increase the company's cash flow and assets.

BE-Smart Esophageal Cancer Test

The BE-Smart Esophageal Cancer Test has multibillion-dollar potential, targeting approximately 7 million endoscopies per year in the US. It aims to enhance endoscopy accuracy and is expected to be commercialized later in 2025.

Crown Medical Collections

Crown Medical is actively working on collecting outstanding COVID testing receivables, with potential significant cash inflows expected in the next few months.

Debt Financing and Liquidity Strategy

ProPhase Labs is focused on debt financing rather than issuing shares, anticipating significant liquidity events in the second half of 2025.

NASDAQ Listing Compliance

The company anticipates receiving a 6-month extension to maintain NASDAQ listing compliance, meeting all criteria except stock price.

Prophase Labs (PRPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PRPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	- / -	-0.35	―	―	―
Aug 07, 2025	2025 (Q2)	-0.15 / -	-0.33	―	―	―
May 20, 2025	2025 (Q1)	- / -0.13	-0.07	-85.71% (-0.06)	―
Mar 31, 2025	2024 (Q4)	-0.18 / -0.13	-0.07	-85.71% (-0.06)	―
Nov 13, 2024	2024 (Q3)	-0.31 / -0.35	-0.3	-16.67% (-0.05)	―
Aug 14, 2024	2024 (Q2)	-0.08 / -0.33	-0.2	-65.00% (-0.13)	―
May 09, 2024	2024 (Q1)	-0.28 / -0.07	0.03	-333.33% (-0.10)	―
Mar 15, 2024	2023 (Q4)	-0.26 / -0.51	-0.15	-240.00% (-0.36)	―
Nov 09, 2023	2023 (Q3)	-0.20 / -0.30	0.06	-600.00% (-0.36)	―
Aug 10, 2023	2023 (Q2)	-0.14 / -0.20	0.4	-150.00% (-0.60)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PRPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$0.32	$0.33	+3.13%
May 20, 2025	$0.32	$0.33	+3.13%
Mar 31, 2025	$0.44	$0.40	-9.09%
Nov 13, 2024	$0.74	$0.77	+4.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Prophase Labs (PRPH) report earnings?

Prophase Labs (PRPH) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Prophase Labs (PRPH) earnings time?

Prophase Labs (PRPH) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PRPH EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing